Similar results were observed with brachyury-specific T cells or TRAIL in PC9 cells (Figure 4b), where simultaneous erlotinib administration significantly enhanced tumor lysis above the level observed with each treatment alone. This evidence concerns the gene TBX1 and neoplasm.